Synthetic universal flu vaccine designed to protect against many flu strains
Synthetic multi-component influenza vaccines to elicit broad immunity
This project is developing a lab-made flu vaccine meant to produce broad protection for people, especially older adults, infants, and those with weakened immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11225082 on NIH RePORTER |
What this research studies
Researchers are chemically building a vaccine made from conserved pieces of the influenza virus combined with an immune-boosting component and testing whether it triggers strong B‑cell and T‑cell responses. They will first test the vaccine in the lab and in mice to measure antibody and T‑cell activity and to see if it protects against different influenza A strains. The team builds on prior work where a similar multi-component design produced robust immune responses in mouse models. If results are promising, the approach would be refined toward later-stage testing that could include human trials.
Who could benefit from this research
Good fit: People most likely to benefit in future trials would include those at high risk from flu such as older adults, infants, and immunocompromised individuals once human testing begins.
Not a fit: During the current lab and animal testing phase, people seeking immediate protection will not benefit, and those with non-influenza respiratory illnesses would not be helped by this vaccine.
Why it matters
Potential benefit: If successful, this work could lead to a broadly protective or ‘universal’ flu vaccine that reduces severe illness and the need for seasonal updates.
How similar studies have performed: Related multi-component vaccine approaches have produced strong immune responses and protection in prior mouse studies, but universal flu vaccines remain largely experimental and only a few strategies have reached early human testing.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Boons, Geert-Jan — University of Georgia
- Study coordinator: Boons, Geert-Jan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.